Log In
BCIQ
Print this Print this
 

meloxicam (N1539)

  Manage Alerts
Collapse Summary General Information
Company Recro Pharma Inc.
DescriptionCyclooxygenase-2 (COX-2) inhibitor developed using NanoCrystal technology
Molecular Target Cyclooxygenase-2 (COX-2)
Mechanism of ActionCyclooxygenase-2 (COX-2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat acute postoperative pain following a bunionectomy; Treat acute postoperative pain following abdominoplasty; Treat moderate to severe acute post-operative pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$170.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/09/2015

$170.0M

0

Undisclosed

Get a free BioCentury trial today